Disc Medicine received a Complete Response Letter from the FDA rejecting its new drug application for bitopertin due to insufficient evidence, causing its stock to fall 22% on February 13, 2026. The Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit on behalf of shareholders who may have been misled by the company. Investors who purchased Disc Medicine securities might be eligible for compensation without upfront costs through this legal action. Interested parties can join the class action by contacting the Rosen Law Firm.
Bittensor has overhauled its emission model with the Taoflow upgrade, shifting from price-based to real-time capital flow-based rewards. Subnets that fail to attract net positive staking flows receive zero emissions, creating a survival-of-the-fittes...
Disc Medicine, Inc. faced a 22% stock price drop after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. The Rosen Law Firm is investigating potential securities ...
An attacker exploited a flaw in the third-party SquidRouterModule to drain $3.2 million from 86 Gnosis Safe wallets on Ethereum and Base within two hours. The vulnerability involved improper identity validation, allowing the attacker to impersonate a...
A pseudonymous US man filed a lawsuit in New York seeking ownership of over 39,000 dormant Bitcoin addresses estimated to hold about 3.7 million BTC worth $285 billion. The suit claims these wallets are abandoned property under New York's lost-proper...
Polygon co-founder Sandeep Nailwal announced the launch of Open Money Stack, a new blockchain platform aimed at neobanks and fintech firms. This platform provides an integrated API covering wallets, payments, and compliance, simplifying financial ser...
